In breast cancer cell lines (MCF7 and MDA-MB-231), silencing of YTHDF1 increased sensitivity to Adriamycin, cisplatin, and olaparib, highlighting the significance of YTHDF1 in drug resistance and DNA damage repair. Here, YTHDF1 is linked to breast carcinoma.